REGENXBIO Inc. financial data

Symbol
RGNX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
9804 Medical Center Drive, Rockville, MD
Fiscal year end
December 31
Former names
ReGenX Biosciences, LLC (to 11/7/2013)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 315 % -0.82%
Debt-to-equity 69.5 % +6.04%
Return On Equity -70.7 % -18.7%
Return On Assets -41.7 % -15.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.5M shares +12.6%
Common Stock, Shares, Outstanding 49.5M shares +12.6%
Entity Public Float 805M USD -18.3%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 50.8M shares +15.6%
Weighted Average Number of Shares Outstanding, Diluted 50.8M shares +15.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 84.3M USD -15.1%
Research and Development Expense 214M USD -10.6%
General and Administrative Expense 75.6M USD -16.5%
Costs and Expenses 330M USD -8.62%
Operating Income (Loss) -246M USD +6.15%
Nonoperating Income (Expense) 6.92M USD +390%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -264M USD +5.98%
Income Tax Expense (Benefit) -41K USD -1125%
Net Income (Loss) Attributable to Parent -239M USD +8.34%
Earnings Per Share, Basic -5.02 USD/shares +16.1%
Earnings Per Share, Diluted -5.02 USD/shares +16.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 56.6M USD +6.73%
Marketable Securities, Current 199M USD -20.1%
Cash, Cash Equivalents, and Short-term Investments 279M USD -23.6%
Accounts Receivable, after Allowance for Credit Loss, Current 23.6M USD -15.8%
Other Assets, Current 23.3M USD -0.07%
Assets, Current 313M USD -14.3%
Property, Plant and Equipment, Net 121M USD -11.1%
Operating Lease, Right-of-Use Asset 55.3M USD -10.5%
Other Assets, Noncurrent 4.33M USD -7.22%
Assets 519M USD -18.1%
Accounts Payable, Current 19.5M USD -10.7%
Employee-related Liabilities, Current 14.3M USD -3.56%
Contract with Customer, Liability, Current 144K USD -67.4%
Liabilities, Current 103M USD -19.3%
Operating Lease, Liability, Noncurrent 76.3M USD -9.18%
Other Liabilities, Noncurrent 3.58M USD -42.1%
Liabilities 218M USD -19.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -582K USD +92.1%
Retained Earnings (Accumulated Deficit) -881M USD -37.2%
Stockholders' Equity Attributable to Parent 301M USD -17%
Liabilities and Equity 519M USD -18.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.5M USD +31.5%
Net Cash Provided by (Used in) Financing Activities 121M USD
Net Cash Provided by (Used in) Investing Activities 13.2M USD -79.1%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 49.5M shares +12.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 78.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 58.6M USD +6.05%
Deferred Tax Assets, Valuation Allowance 280M USD +32.8%
Deferred Tax Assets, Gross 324M USD +24.9%
Operating Lease, Liability 89.3M USD -5.81%
Payments to Acquire Property, Plant, and Equipment 557K USD -88.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -232M USD +7.1%
Lessee, Operating Lease, Liability, to be Paid 1.3M USD
Property, Plant and Equipment, Gross 190M USD 0%
Operating Lease, Liability, Current 7.72M USD +16.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.8M USD +3.94%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.9M USD +5.33%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33M USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD +1.43%
Deferred Tax Assets, Operating Loss Carryforwards 61.9M USD +143%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 100K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10M USD -19.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 43.3M USD -9.91%
Share-based Payment Arrangement, Expense 37.3M USD -9.87%
Interest Expense 5.41M USD -61.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%